TRISCEND II Trial Shows Edwards EVOQUE System Significantly Outperforms Medical Therapy Alone In Treating Severe Tricuspid Regurgitation, Achieving 95.3% TR Elimination And Marked Improvements In Symptoms And Quality Of Life At One Year; Results Published In NEJM And JACC
Portfolio Pulse from Benzinga Newsdesk
The TRISCEND II trial demonstrated that Edwards Lifesciences' EVOQUE system significantly outperforms medical therapy alone in treating severe tricuspid regurgitation, achieving 95.3% TR elimination and improving symptoms and quality of life at one year. Results were published in NEJM and JACC.
October 30, 2024 | 3:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Edwards Lifesciences' EVOQUE system has shown significant success in the TRISCEND II trial, outperforming medical therapy in treating severe tricuspid regurgitation with 95.3% TR elimination and improved patient outcomes.
The EVOQUE system's success in the TRISCEND II trial, with high TR elimination and improved patient outcomes, is likely to boost investor confidence in Edwards Lifesciences, positively impacting its stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100